Tags

Type your tag names separated by a space and hit enter

Melatonin as an anti-inflammatory agent in radiotherapy.
Inflammopharmacology. 2017 Aug; 25(4):403-413.I

Abstract

Radiotherapy is one of the most relevant treatment options for cancer therapy with or without other treatment modalities including immunotherapy, surgery and chemotherapy. Exposure to heavy doses of ionizing radiation during radiotherapy results in short and long term side effects. It appears that many of these side effects are linked to inflammatory responses during treatment or after prolonged use. Inflammation is mediated by various genes and cytokines related to immune system responses caused by massive cell death following radiotherapy. This phenomenon is more obvious, particularly after exposure to clinical doses of radiotherapy. Inflammation is involved in the amplification of acute responses, genomic instability and also long term pathological changes in normal tissues. Moreover, inflammation attenuates responses of the tumor to radiotherapy through some mechanisms such as angiogenesis. Thus, the management of inflammation is one of the most interesting aims in cancer radiotherapy. Melatonin, known as a natural product in the body, has been of much interest for its anti-inflammatory properties. Some studies have proposed melatonin as a novel anti-inflammation agent. This literature review will concentrate on the anti-inflammatory properties of melatonin that may help the management of different inflammatory signaling pathways in both tumor and normal tissues.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Najafi M
Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Shirazi A
Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran. shirazia@sina.tums.ac.ir.
Motevaseli E
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. e_motevaseli@tums.ac.ir.
Rezaeyan AH
Department of Medical Physics, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Salajegheh A
Department of Radiology, Faculty of Paramedical, Shiraz University of Medical Sciences, Shiraz, Iran.
Rezapoor S
Department of Radiology, Faculty of Paramedical, Tehran University of Medical Sciences, Tehran, Iran.

MeSH

AnimalsAnti-Inflammatory AgentsDermatitisHumansInflammationMelatoninMucositisNeoplasmsOxidative StressRadiation Injuries

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28255737

Citation

Najafi, M, et al. "Melatonin as an Anti-inflammatory Agent in Radiotherapy." Inflammopharmacology, vol. 25, no. 4, 2017, pp. 403-413.
Najafi M, Shirazi A, Motevaseli E, et al. Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology. 2017;25(4):403-413.
Najafi, M., Shirazi, A., Motevaseli, E., Rezaeyan, A. H., Salajegheh, A., & Rezapoor, S. (2017). Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology, 25(4), 403-413. https://doi.org/10.1007/s10787-017-0332-5
Najafi M, et al. Melatonin as an Anti-inflammatory Agent in Radiotherapy. Inflammopharmacology. 2017;25(4):403-413. PubMed PMID: 28255737.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Melatonin as an anti-inflammatory agent in radiotherapy. AU - Najafi,M, AU - Shirazi,A, AU - Motevaseli,E, AU - Rezaeyan,A H, AU - Salajegheh,A, AU - Rezapoor,S, Y1 - 2017/03/02/ PY - 2016/12/08/received PY - 2017/02/19/accepted PY - 2017/3/4/pubmed PY - 2018/4/12/medline PY - 2017/3/4/entrez KW - Immune system KW - Inflammation KW - Melatonin KW - Oxidative stress KW - Radiotherapy SP - 403 EP - 413 JF - Inflammopharmacology JO - Inflammopharmacology VL - 25 IS - 4 N2 - Radiotherapy is one of the most relevant treatment options for cancer therapy with or without other treatment modalities including immunotherapy, surgery and chemotherapy. Exposure to heavy doses of ionizing radiation during radiotherapy results in short and long term side effects. It appears that many of these side effects are linked to inflammatory responses during treatment or after prolonged use. Inflammation is mediated by various genes and cytokines related to immune system responses caused by massive cell death following radiotherapy. This phenomenon is more obvious, particularly after exposure to clinical doses of radiotherapy. Inflammation is involved in the amplification of acute responses, genomic instability and also long term pathological changes in normal tissues. Moreover, inflammation attenuates responses of the tumor to radiotherapy through some mechanisms such as angiogenesis. Thus, the management of inflammation is one of the most interesting aims in cancer radiotherapy. Melatonin, known as a natural product in the body, has been of much interest for its anti-inflammatory properties. Some studies have proposed melatonin as a novel anti-inflammation agent. This literature review will concentrate on the anti-inflammatory properties of melatonin that may help the management of different inflammatory signaling pathways in both tumor and normal tissues. SN - 1568-5608 UR - https://www.unboundmedicine.com/medline/citation/28255737/Melatonin_as_an_anti_inflammatory_agent_in_radiotherapy_ L2 - https://medlineplus.gov/cancerchemotherapy.html DB - PRIME DP - Unbound Medicine ER -